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Long-actingThis article reviews key methodological considerations for clinical trials that utilize explanatory and pragmatic
trial designs and relates these contrasting approaches to the interpretation of results from comparisons of oral
versus long-acting injectable (LAI) antipsychotics in schizophrenia. Explanatory randomized controlled trials
(RCTs) generally measure the efﬁcacy of a treatment in a homogeneous population with intensive, frequent,
and often clinical trial-speciﬁc assessments. In contrast, pragmatic trials measure effectiveness in routine clinical
practice and frequently aim to inform choices between treatments. Comparative effectiveness outcomes with
pragmatic designs in naturalistic settings for schizophrenia treatments are of increasing interest to healthcare
providers because outcomes of treatment (both efﬁcacy and safety) may vary signiﬁcantly when identiﬁed in
an explanatory setting compared with a naturalistic pragmatic setting. Indeed, it has been suggested that the
inconsistent outcomes observed in trials comparing oral and LAI antipsychotic medications may be a function
of the use of explanatory or pragmatic trial designs.
In practice, clinical trial designs are seldom purely explanatory or pragmatic. To identify the predominant orien-
tation of a trial, one must consider multiple features. This paper reviews the relative impact of these features
when comparing LAI and oral antipsychotic treatments and makes recommendations for improving these com-
parative designs.
© 2014 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The question of whether long-acting injectable (LAI) antipsychotics
offer meaningful advantages over oral antipsychotics in the treatment
of individuals with schizophrenia has been addressed in recent studies
with inconsistent results (Chue et al., 2005; Bai et al., 2006; Emsley
et al., 2008; Weiden et al., 2009; Gaebel et al., 2010; Macfadden et al.,
2010; Rosenheck et al., 2011; Schooler et al., 2011; Weiden et al.,
2012; Zhornitsky and Stip 2012; Barrio et al., 2013). Meta-analytical
reviews of these studies have been similarly inconsistent (Leucht
et al., 2011; Fusar-Poli et al., 2013; Kirson et al., 2013; Kishimoto et al.,
2013, 2014). Consequently, whether treatment with oral or LAI formu-
lations of antipsychotics produces meaningfully different outcomes re-
mains a matter of debate.125 Trenton-Harbourton Road,
609 730 3232.
hooler@gmail.com
.
-NC-ND license.Pharmacological differences are unlikely to explain potential differ-
ences in treatment outcomes between LAI and oral formulations be-
cause the medications in both groups have similar (Weiden et al.,
2009; Gaebel et al., 2010; Macfadden et al., 2010; Schooler et al., 2011;
Weiden et al., 2012; Zhornitsky and Stip 2012; Barrio et al., 2013),
sometimes identical (Chue et al., 2005; Bai et al., 2006; Emsley et al.,
2008), pharmacological mechanisms. Rather, potential differences in
effectiveness between LAI and oral antipsychotics aremost likely attrib-
utable to the fact that, in clinical practice, administration of an LAI
guarantees medication adherence during the postinjection treatment
interval. In addition, failure to receive a follow-up injection signals the
onset of nonadherence. In contrast, adherence to oral treatment is near-
ly always uncertain.
Explanatory randomized controlled trials (RCTs) of pharmacological
treatments are designed to study the efﬁcacy and safety of molecules
under well-controlled circumstances. Subjects selected must under-
stand and consent to both treatment and assessment procedures and
are expected to adhere to the protocol. Further, a great deal of attention
is paid to ensuring and reinforcing protocol compliance. Such care may
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formulations that are present in actual practice. Pragmatic studies, in
which differences in adherence are less constrained, seem more likely
to mirror real-world practice and may offer advantages.
The aims of this article are (1) to review in detail differences
between explanatory and pragmatic trial designs, (2) to show how
these design considerations may impact interpretation of disparate
ﬁndings from studies that have compared LAIs versus oral medications,
and (3) to offer recommendations for such studies going forward.
2. Design considerations
2.1. Speciﬁcation of study objectives
Studies designed to address one objective may not be appropriate
for addressing others, even if the objectives are related. Indeed, if an
inappropriate study design is selected, results may be misleading.
The speciﬁc study objective and design characteristics must be aligned
(American Psychological Association, 2010).
Careful deﬁnition of the study objective is particularly critical when
one is looking for potential treatment differences between oral and LAI
antipsychotic medications. First, it must be determined if the study
focus is to ascertain whether the medication is inherently effective
and safe, or whether the medication is effective and safe in naturalistic
practice settings (i.e., whether a more explanatory or a more pragmatic
design is needed [Section 2.2]). Then, the trial design must be selected
according to whether the study is to show equivalence, non-inferiority,
or superiority over the comparator treatment. Each approach requires a
very different study design and analytical method.
2.2. Pragmatic versus explanatory design
Explanatory clinical trials generally measure efﬁcacy of a treatment
in a relatively homogeneous population by performing intensive,
frequent, and standardized clinical assessments, whereas pragmatic tri-
alsmeasure effectiveness inmore heterogeneous populations in routine
clinical practice. Actual clinical trial designs represent a spectrum of
pragmatic and explanatory approaches; seldom is a trial purely explan-
atory or purely pragmatic (Thorpe et al., 2009). Several study design
domains are particularly relevant for characterizing a study along the
pragmatic–explanatory continuum. These include design choices
around (1) patient population selection; (2) site selection and medical
practice setting/practitioner expertise found at the site; (3) degree of
intervention ﬂexibility allowed during the evaluation; (4) measures of
primary and secondary trial outcomes; (5) participant adherence to
treatment and to assessment; and (6) whether subjects are randomly
assigned to treatment (Table 1).
2.3. Speciﬁc study design features relevant to pragmatic–explanatory
continuum
2.3.1. Patient population selection
A key consideration in study design involves the deﬁnition of the
population to be studied. Explanatory clinical trials designed to demon-
strate intrinsic efﬁcacy and safety of a treatment seldom randomly
sample from the total population of potential patients with the illness
that needs to be treated. Indeed, to minimize interpretive confounds
from concomitant medications and comorbid conditions, restrictive
selection criteria for potential subjects often identify constrained popu-
lation subgroups for study. Most studies further select subjects who are
likely to be adherent with treatment and trial procedures by excluding
patients with a history of noncompliance or substance abuse (Thorpe
et al., 2009). Additionally, patients enrolled in clinical trials are more
likely to adhere to treatment regimens when they are aware that their
compliance is being strictly monitored. This is speciﬁcally seen in
schizophrenia trials (Gutiérrez-Casares et al., 2010; Kirson et al.,2013). Other exclusion criteria in trials investigating the treatment of
schizophrenia frequently eliminate participants at highest risk of unfa-
vorable outcomes (treatment resistant) and those with psychiatric
and medical conditions that might interfere with assessment of the
safety and efﬁcacy of the treatment(s) being evaluated (Bai et al.,
2006; Fleischhacker et al., 2012). Although this process is useful in
selecting subjects for whom observed efﬁcacy and safety data are
most clearly attributable to the study drug, it is unlikely to yield a sam-
ple population that is fully representative of patients who will be treat-
ed in real-world clinical practice settings.
Pragmatic trials strive to enroll all patients whomeet the basic entry
criteria for the population of interest deﬁned by the study question
(i.e., ideally, no additional restrictions are applied to the predeﬁned
population of interest). Thus, with perfect pragmatic designs of ade-
quate size, considerations such as responsiveness, adverse events,
and treatment adherence should be fully reﬂective of the population
identiﬁed by the study question/hypothesis. However, even prospective
trials that aim to be pragmatic are constrained by sample size and selec-
tion biases arising from the need for informed consent, the range of pa-
tients available at the study site, and the selection biases that draw
patients to that site. For example, in comparing LAIs to oral treatments,
patient reluctance to receive injections can reduce the likelihood that
such patients will enroll in the trials and increase dropout, thus altering
the representativeness of the trial population (Kishimoto et al., 2013,
2014). These selection issues represent limitations for nearly all prag-
matic clinical trials. Nevertheless, despite their imperfections, well-
conducted pragmatic trials better reﬂect the broad range of patients
found in regular clinical practice, and results of pragmatic trials will be
more broadly generalizable than those from explanatory trials.
When data from schizophrenia trials comparing LAI and oral treat-
ment outcomes are compared, additional patient characteristics are
relevant. These include severity and stability of symptoms, duration of
follow-up, and clinical history such as duration of illness and number
of prior relapses/hospitalizations. For example, differences in efﬁcacy
between LAI and oral treatments may be more evident in recently diag-
nosed patients, perhaps because they are less likely to be adherent to
treatment than more chronically ill patients (Subotnik et al., 2012).
Attitudes toward taking medicine and, by implication, adherence to
treatment may be affected by local culture, ethnicity, age, and gender
and may affect relative treatment response.
2.3.2. Site selection and medical practice setting/practitioner expertise
The representativeness of the skill sets of practitioners and the
characteristics of the clinical settings relative to those in which the
treatment will be applied also affect the degree to which a trial is ex-
planatory or pragmatic. Local standards of clinical practice, the skill
and experience of practitioners, and the availability of concomitant or
alternative treatment options may affect treatment outcomes. In ex-
planatory trials, experienced practitioners in optimal clinical set-
tings are usually most desirable. On the other hand, a prototypic
pragmatic study selects broadly, although rarely randomly, from
the range of relevant clinical practices the settings in which treat-
ment is to be given. Treatment settings and practices also change
over time. This is relevant when the results of both explanatory
and pragmatic trials that have been completed across an extensive
time span are evaluated in meta-analyses. Meta-analyses that com-
pare LAI antipsychotics versus oral medications may be confounded
by differences in treatment practice that may have been prevalent
when alternative treatment options were prevalent. For explanatory
and most prospective pragmatic trials, a standardized protocol and
systematic training are used to reduce variability in assessment and
experience. However, adherence to these study-speciﬁc standards
and training reduces their pragmatic character.
To assess the generalizability of clinical trial results with LAI versus
oral antipsychotics, it is necessary to understand (1) the heterogene-
ity of schizophrenia, (2) the varieties of clinical practice applied to
Table 1
The difference in design choices between explanatory and pragmatic studies.
Explanatory Pragmatic
Study objectives To determine efﬁcacy and safety in a controlled environment To determine efﬁcacy and safety in a real-world clinical en-
vironment
Population selection Speciﬁc selection criteria may not be fully representative of the population requiring
treatment; extensive exclusion criteria
Includes all patients who meet basic inclusion criteria;
minimal exclusion criteria
Site selection Experienced practitioners in an optimal controlled clinical environment Sites are selected broadly from relevant settings that provide
treatment to the target population
Intervention during trial Limited ﬂexibility; changes in randomized treatment may end study participation Highly ﬂexible; participants retained in treatment even after
change of randomized assignment
Outcome measures Primary measures are often not applicable to a real-world situation (e.g., use of rating
systems or scales not used in routine clinical practice)
Include objective measures pertinent to clinicians, patients,
and public health ofﬁcials
Adherence Maximized to allow accuracy in analysis of efﬁcacy and safety Allowed to reﬂect a real-world clinical environment
Randomization Random assignment to treatment Often incorporate randomization; completely
nonrandomized trials introduce selection bias
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have been sampled in the clinical trial.
2.3.3. Intervention ﬂexibility during evaluation
Explanatory trials generally constrain intervention ﬂexibility to
ensure that information truly reﬂects the intrinsic efﬁcacy and safety
of the drug at the speciﬁc doses or dose ranges being evaluated. Con-
versely, interventions in the most pragmatic trials are highly ﬂexible
so as to reﬂect real-world practice and allow for broad decision making
by the clinician. In prospective, randomized pragmatic trials, subjects
may be allowed to stop, adjust dose, or switch from their randomly
assigned treatment to improve efﬁcacy and tolerability (Macfadden
et al., 2010). However, the documentation of these practices required
for prospective clinical trials is likely to reduce the pragmatic character-
istics of the trial and may affect the outcome.
2.3.4. Choice of primary and secondary trial outcomes
In explanatory trials, the primary outcome measure usually ad-
dresses short-term consequences of the intervention. The measures
most commonly used are speciﬁc symptoms that may not reﬂect
functional improvement. A 6-point change on a rating scale, such as
the Young Mania Rating Scale (Turkoz et al., 2013), is not an intuitively
meaningful value for the practicing clinician, and it may not be correlat-
ed with functional improvement. Pragmatic trials, on the other hand,
generally include primary outcome measures that are objectively mea-
sured and intuitively meaningful to most stakeholders, including the
patient and public health ofﬁcials. In the comparison between LAIs
and oral medications for schizophrenia, these can include such out-
comes as hospitalization rates (Grimaldi-Bensouda et al., 2012) or
time to relapse (Macfadden et al., 2010).
Because explanatory trials focus on the efﬁcacy and safety of a par-
ticular treatment, outcomes are deﬁned by change in a measure or
time to a speciﬁed symptomatic change during randomized treatment.
Information on the subject's actual condition at a predeﬁned endpoint
in time is usually not required. With such designs, the treatment may
have been discontinued before a predeﬁned follow-up periodwas com-
pleted. In contrast, pragmatic trials aim to measure functionally impor-
tant outcomes after a prespeciﬁed time interval, regardless of whether
randomized treatment is ongoing or discontinued. The best pragmatic
studies follow all subjects for the predeﬁned interval, regardless of
whether they remain on the assigned treatment. Explanatory trials
seldom have this continued follow-up, and because of early dropouts,
outcome information for a constant follow-up interval must often be
imputed. Imputation of outcomes measured before the deﬁned end-
point is highly problematic, as it is associated with censoring biases.
Because events that occur after early discontinuation may be extremely
relevant to the patient's predeﬁned outcome, great painsmust be taken
to follow all patients in these studies, even if the assigned primary
treatment has been discontinued. Head-to-head pragmatic trials that
allow switching of medications to the alternative study treatment, asis sometimes done in comparisons of LAI and oral antipsychotic treat-
ments, can raise fundamental conundrums regarding appropriate attri-
bution of safety and efﬁcacy outcomes, as, after the point of switch, they
may be a consequence of study treatments or their interaction. In such
instances, this can be addressed only partially by censoring data at the
point of switch to the alternative therapy.
“Relapse” or “time-to-relapse” is frequently used as an explanatory
endpoint in schizophrenia trials. However, “relapse” is a challenging
pragmatic endpoint for several reasons. First, no universal deﬁnition of
“relapse” is available; sometimes it is equated with hospitalization, but
drivers of hospitalization differ by treatment system and change over
time. Also, “relapse” does not address potentially greater efforts to
maintain stability with one treatment rather than another (e.g., in
terms of clinical carewith oral antipsychotics rather than LAIs). Further,
“relapse” is unidimensional and, even in that dimension, does not ade-
quately encompass the various levels of outcome that are short of full
relapse (i.e., relapse rates may not differ, but patients in one group
may be symptomatically improved andhave better long-termoutcomes
or may experience a better quality of life). Clinicians, patients, and
payers are often interested in a summation of overall outcome over a
deﬁned time frame rather than simply the occurrence of a single
event. Other stakeholders (like payers) may be interested in high-
impact events but would want to know their cumulative impact over
a deﬁned time frame for each subject, not just the occurrence of an
event at a single point in time or the time to the ﬁrst event. This is not
to say that “relapse” cannot be a useful outcome measure; rather, that
it must be well deﬁned and should be used in combination with other
validated outcomes that include a spectrum of positive as well as nega-
tive outcome responses. Future trials could further deﬁne the relapse
continuum by including other measures such as improvements from
baseline, exacerbations not leading to relapse, duration of remission of
symptoms (psychoses, negative symptoms, etc.), maintenance of stabil-
ity, and/or maintenance of reductions in violent behavior and in incar-
ceration/arrest/recidivism.
2.3.5. Participant adherence to treatment and to assessment
As has already been discussed, nonadherence must be minimized in
explanatory trials to permit determination of whether results truly per-
tain to the efﬁcacy and safety of the treatments under consideration.
However, nonadherence should be allowed in pragmatic trials, as this
reﬂects a very relevant clinical outcome. In pragmatic trials, assessment
burden and requirements for maintaining treatment adherence should
attempt to reﬂect actual practice for treatment adherence to the treat-
ments under study. Thus, in pragmatic studies comparing LAI and oral
medications, visit frequency may well vary between treatment groups.
This better reﬂects a real-world clinical situation in which the interval
between clinic visits will be determined by the injection interval in
patients receiving LAI medications; visit frequency for those receiving
oral antipsychotics may vary substantially, being as infrequent as once
every 3 months or as frequent as once weekly. Clinic visits and delivery
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medications, but adherence to oral treatments can only be determined
by less deﬁnitive methods. These include self report, pharmacy data,
clinical records, family report, pill counts (manual or electronic), or
serum medication levels (Valenstein et al., 2002; Weiden et al., 2009;
Rosenheck et al., 2011).
2.3.6. Superiority versus noninferiority versus equivalence
Another important aspect of clinical trial design involves whether
the investigation is to be a superiority, a noninferiority, or an equiva-
lence trial. Both explanatory and pragmatic trials can be designed to as-
sess superiority, noninferiority, or equivalence, but these reﬂect
fundamentally different approaches to trial design that entail consider-
ation of study population, endpoints, duration, andmanagement of bias.
Both noninferiority and equivalence trials require the explicit
identiﬁcation of clinically justiﬁed margins and usually require a
larger sample size than that required for superiority trials that use
null hypothesis testing. This can be particularly problematic in trials
of schizophrenia treatments in which recruitment challenges and
high dropout rates make recruitment and retention for follow-up
difﬁcult (Jørgensen et al., 2014). Retention is particularly important
for pragmatic trials where the point of drop out may be the point of
greatest interest.
Further, identifying a superiority margin goes beyond rejection of
the null hypothesis and allows a statement that the difference detected
is meaningful from a clinical or public health perspective. The supe-
riority margin generally represents a public health perspective
rather than an individual patient's perspective, but it should be justi-
ﬁed. Failure to achieve superiority does not represent noninferiority
unless a predeﬁned noninferiority margin has also been met. Rejection
of the null hypothesis does notmean that the two treatments are equiv-
alent. The literature is often unclear about this: Describing trials that
have failed to reject a null hypothesis as showing that treatments are
equivalent is not uncommon. On the other hand, identiﬁcation of
superiority in a noninferiority trial may be clinically relevant if a superi-
ority margin has been predeﬁned.
2.3.7. Randomization
Explanatory clinical trials always involve random assignment to
treatment. Pragmatic trials may incorporate randomization, but ran-
domization compromises the degree to which the trial reﬂects natural-
istic treatment. Nonrandomized pragmatic trials are also an option, but
such studies introduce limitations related to selection bias. These biases
should be explicitly noted in the interpretation and may be addressed
by the use of techniques such as propensity matching (Rosenbaum
and Rubin, 1983; Austin, 2011).
The act of randomization itself may bias results in terms of both
patient and site selection with consequences for generalizability of theTable 2
Recommendations for increasing pragmatism in clinical trials of schizophrenia comparing oral
Trial parameter Recommendation(s)
Treatment schedules ▪Use treatment schedules thatmirror real-world contactwit
oral arm: 1 to 3 monthly, depending on symptoms and loca
• Treatment personnel seenby the patient shouldmodel thos
and may not see a physician or nurse/practitioner at every v
Blinding ▪ Avoid double-blind trials in which all subjects receive injec
and therefore may lead to unrepresentative results
Adherence and treatment
compliance
▪ During clinic visits, staff should use adherence-advancing i
Trial duration ▪ Ideally, duration of follow-up should be at least 1 year; ho
▪ Caveat: Longer trials have greater potential for incomplete
consequent loss of sensitivity to actual treatment response
Dropouts ▪ Diligence to avoid dropouts is critical, as they are a signiﬁc
differentiation begins
▪ Strategies to reduce dropouts could include conducting the
study (e.g., Medicaid, Veterans Affairs). This may, however,results. Patients who consent to participate in randomized controlled
trials at sites that conduct them are willing to be involved with a more
formalized type of care than is standard. A patient who is willing to
participate in such a study has self-identiﬁed at several levels as some-
one who (1) needs medical care; (2) is willing to take treatment; and
(3) is willing to have treatment assigned randomly rather than by
choice. Such patients may be more likely to be adherent to medication
than those not willing to participate in randomized trials, although to
our knowledge, no one has ever formally addressed this question.
Clinical sites that conduct randomized studies may be selected on the
basis of increased skill sets of the practitioners, their ability to provide
more frequent and intense treatment, their attitudes toward that treat-
ment, and their ability to provide support to patients who consent to
random assignment to treatment.
Randomization is the explanatory feature that most often character-
izes trials that seek to bridge the pragmatic–explanatory continuum.
This approach incorporates a major strength of explanatory designs
but does introduce the limitations noted above.
3. The explanatory–pragmatic continuum
Many studies incorporate both explanatory and pragmatic ele-
ments. Such an approach is helpful to researchers who seek to gain
insight into complicated clinical questions, but recognition of the
characteristics of the trial is important, as these limit interpretation
of the results (Tosh et al., 2011; Bossie and Alphs 2013). For example,
because explanatory approaches usually put constraints on visit fre-
quency and the content of those visits, such that they may alter adher-
ence, results from comparisons of oral and LAI antipsychotics may be
dependent on whether this explanatory feature is incorporated into
the trial.
4. Recommendations
In the design, review, and interpretation of clinical trials, the primary
questions for a study and for the stakeholders are critical considerations.
If the question being addressed concerns the safety and efﬁcacy attri-
butes of a particular treatment, the design should be more explanatory.
If the question concerns how safe and effective the treatment is in
naturalistic clinical practice, the design should be more pragmatic. It is
important to recognize that whatever approach is taken, any particular
clinical trial will have limitations, and multiple studies are necessary
if one is to gain complete understanding of the safety, efﬁcacy, and
role in clinical practice of a novel treatment. Examination of study
approaches used when oral and LAI antipsychotic treatments are
compared is particularly critical, as outcomes may be strongly inﬂu-
enced by design decisions. Table 2 summarizes the steps that can be
taken to increase the pragmatism of studies that compare oral versusand LAI antipsychotic treatment response.
h doctors and nurses as seen in naturalistic practice (i.e., LAI arm: 2weekly to 1monthly;
l practice)
e seen in standard practice. For instance, LAI patientsmay receive injections from a nurse
isit
tions and tablets (double-dummy designs) because they do not reﬂect clinical practice
nterventions as they normally would during customary practice
wever, if the goal is to detect outcomes beyond relapse, the trial may be longer
follow-up with possible regression to the mean, dependent variable censoring, and
ant source of bias; the point of dropout is perhaps the point at which greatest
trial in the context of an outcome tracking system that is independent of the primary
introduce other selection biases
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or similar psychotic disorders. Reports of such studies should incorpo-
rate discussion of the degree to which they incorporated explanatory
and pragmatic characteristics and how these inﬂuence interpretation
of results.
5. Conclusions
Once basic questions of safety and efﬁcacy have been addressed,
stakeholders such as healthcare providers and payers increasingly de-
sire information about comparative outcomes with pragmatic designs.
Pragmatic studies (sometimes called effectiveness research) have unique
characteristics that differ from those of more familiar explanatory trials.
These distinctions are particularly critical in evaluating outcomes from
studies comparing LAIs versus oral antipsychotic treatments when
pragmatic or explanatory design features may fundamentally affect
observed outcomes.
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